Učitavanje...

Re-purposing cancer therapeutics for breast cancer immunotherapy

After decades of work to develop immune-based therapies for cancer, the first drugs designed specifically to engage the host anti-tumor immune response for therapeutic benefit were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autor: Emens, Leisha A.
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2012
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3582212/
https://ncbi.nlm.nih.gov/pubmed/22454154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1247-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!